Complete digital access to quality FT journalism with expert analysis from industry leaders. Pay a year upfront and save 20%.

MoonLake Immunotherapeutics (NASDAQ:MLTX) develops the tri-specific nanobody Sonelokimab (SLK), a chemical that targets and penetrates difficult-to-reach inflammatory regions.

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar ...

MoonLake Immunotherapeutics' shares have dipped recently, with a catalyst vacuum until mid-2025 when pivotal trial data for hidradenitis suppurativa (HS) is expected. Read the full report.

MoonLake stock has seen a 400% increase in value since its listing on the Nasdaq, and has raised over $450 million through equity offerings. Read more here. Skip to content.

ZUG, Switzerland, July 25, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory ...

MoonLake Immunotherapeutics AG. Agreement with Hercules Capital significantly increases financial and operational strength, provides up to $500 million in capital with no dilution to shareholders ...

MoonLake has recently announced the successful outcome of its end-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA) the E.U. European Medicines Agency (EMA), with both ...

MoonLake Immunotherapeutics AG. New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase ...

MoonLake Immunotherapeutics Media & Investors Relations . Carla Bretes, Director IR & External Communications. [email protected]. ICR Healthcare . Mary-Jane Elliott, Namrata Taak, Ashley Tapp.